Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-01-27

Clinical Trial Update: Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pan-VEGF blockade for retinopathy of prematurity was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pan-VEGF blockade (pan-VEGF inhibitor)

Snippet

Sponsor: Vision Research Foundation | Conditions: Retinopathy of Prematurity | Phase 1 | Status: TERMINATED